Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s WegovyThe US Food and Drug Administration (FDA) gave the green light on Wednesday to a new oral weight-loss medication developed by the Indianapolis-based pharmaceutical company Eli Lilly.Known as orforglipron or brand name Foundayo, the once-daily tablet becomes the second GLP-1 drug in pill form to hit the market in a short span of time, arriving after Novo Nordisk’s Wegovy pill received approval in December. Continue reading...
Več na: https://www.theguardian.com/us-news/2026/apr/01/new-weight-loss-pill-glp-1-foundayo